Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14, SHA:600329) plans to provide guarantees of up to a total of 2.46 billion yuan to affiliates Tianjin Pharmaceutical Group Taiping Medicine and Tianjin Zhongxin Medicine, according to a Friday filing on the Singapore Exchange.
The proposed guarantees, subject to shareholder approval, align with the company's 43.35% stake in Taiping Medicine.
The move aims to support the two firms' financing needs, but investors are cautioned as both entities have asset-liability ratios exceeding 70%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.